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Endometriosis is a chronic disease, influenced by internal and external environ-
ment, with long duration from intrauterine life with acme during childbearing, 
when it is associated to chronic pelvic pains, and infertility/subfertility. DNA hyper-
methylation of endometrial promoter PRs Hox genes and DNA hypomethylation 
of promoter ERβ gene is a possible explanation of estrogen dominance, progressive 
loss of progesterone signaling, followed by progesterone resistance in ectopic, and 
progesterone attenuance in eutopic endometrium, for failure of hormone therapy 
(HT), repeated recurrences after surgery, cancers after long time evolution. Animal 
models, human trials demonstrated progesterone (P4) and progestins influences 
over progression of disease pathological characteristics, associated to endometrial 
ER, PR aberrant expressions: ERα loss, and abnormal PRB/PRA ratio. P4 supple-
mentation before mice induced-endometriosis protected from PRs depletion, action 
that can be translated in women according to the difference of 7 to 12 years between 
histologic onset and clinical symptoms/signs, parallel to progressive loss of PRs and 
PR-mediated signaling in ectopic and eutopic endometria. The animal studies have 
shown that a DNA methylation inhibitor alleviates lesion growth, and induces PRs 
target gene expression restoration. Continuous/extended contraceptives, dienogest- 
a new progestin, GnRH agonists/antagonists, aromatase inhibitors, SERM, SPRM, 
combinated molecules are therapeutic options/perspectives aiming restoration 
endometrial estrogen-progesterone balance, without disease’s cure. HT may be 
active alone, or surgery associated.
Keywords: endometriosis, estrogen dominance, progesterone resistance/attenuance, 
timing, progesterone/progestins, DNA methylation inhibition
1. Introduction
Urgent innovations are demanded in endometriosis management, which 
should start by deeper undestanding of disease core features, with disease dif-
ferent phenotypes and idiosyncrasies. Endometriosis, a chronic inflammatory 
and immune disease, dependent on environement factors, genes- Hox genes 
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code (HOXA10/HOXA11), epigenetics, and ovarian steroid hormones, with their 
receptors and coregulators in the eutopic endometrium and ectopic sites, was 
demonstrated to have a long duration of progress from intrauterine life, latency 
in childhood, and acme during reproductive years [1–3] with reappearance in 
postmenopause when hormone replacement therapy, or even without [4]. This 
fact permits therapeutic intervention to correct endometrial abnormal functions 
during menstrual cycle, to prepare decidua receptivity for successful egg implanta-
tion in women with minimal or mild to moderate endometriosis, in order to avoid 
the severe stages, and lack of response to therapy, considering that progesterone 
resistance is an acquired property of eutopic endometrium [5]. The therapeutic 
aims are to prevent, or at least to stop the progressive damages induced by ectopic 
endometriotic lesions in the uterus, entire genital tract, and in extra-uterine sites 
by the endometrial mezenchymal stromal/stem/progenitor cells with their specific 
migratory, adhesive, and invasive properties, with their genome changes when are 
outside the uterus, to influence the self- protected endometriotic lesions [6] and 
to ensure a normal eutopic endometrial cycle functioning, with normal ovarian 
steroid hormones receptors distribution during menstrual cycle. The aims can be 
individually accomplished if therapy is started from early stages of illness, by mov-
ing from pure hormonal therapy to drug combination, or novel molecules- SERMs, 
SPRMs which can escape the disrupted homeostatic mechanisms characteristic for 
endometriosis [7].
One may propose and discuss a perspective “timing” of endometriosis treat-
ment, to maintain or for an early restoration of endometrial estrogen- progesterone 
receptors natural balance [8] being recognized a still delay in diagnosis, and 
treatment [9] delay that permits the evolution of genital damages by progressing 
endometriosis, and in time the risk of atypical endometriosis, and cancers which is 
very difficult to be assessed clinically, without specific biochemical markers [10].
The incidence of endometriosis of one case in 10 women of reproductive age [11, 
12] or around 17% [13] is increasing when one assseses infertility and chronic pelvic 
pains - up to 50% [14] respectively up to 60% [15] recently being estimated 176 mil-
lion women worldwide, making endometriosis as common as diabetes mellitus [16].
There are three distinct forms of disease according to ectopic sites of endome-
trial-like tissue location (peritoneal, ovarian and rectovaginal endometriosis), each 
of them being associated with specific symptoms, although dysmenorrhea, and 
chronic non-menstrual pelvic pains, dyschezia, dyspareunia are the most frecquent 
[17] The literature makes some differences regarding the score of endometriosis, 
namely the ENZIAN classification/score describes superficial (less than 1 mm), 
intermediate (2 to 4 mm), deep (greater than or equal to 5 mm), and very deep 
implants (greater than 10 mm) [18]. The ENZIAN score was proposed of the 
revised American Society of Reproductive Medicine score (1996) [19], which was 
demonstrated to be less adequate to clinics, and the ENZIAN score was recently 
reviewed by experts in imagistic and surgical diagnosis [20]. So endometriosis has 
a similarity to oncology with 4 stages of evolution, with the difference of missing 
nuclear atypia [21] but with possible evolution to malignancy in 1% cases [1, 22] or 
further it may be associated to hematopoietic and breast cancer (HR of 1,3–95% 
CI 1.1–1.4, in Swidish women) [23] and ovarian cancer, − OR of 1.73, (95% CI: 
1.10−2.71) on a pool of women from different continents- Australia, Canada, 
Denmark, USA, during 10 years (1989–1999) with previous endometriosis [24]. The 
natural history of endometriosis is uncertain, e.g. it is not known whether super-
ficial peritoneal endometriosis (SPE) can progress to become another subtype, 
regress spontaneously, or whether disease progression (or lack of treatment) can 
lead to problems with infertility, and there is poor correlation between pain severity 
and the amount, location, and subtype of the ectopic lesions [16].
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The literature does not mention a conclusive noninvasive diagnostic available 
tool to allow early detection of endometriosis, the delay in detection being of 
7–12 years of latency from symptoms onset to the definitive diagnosis, and even in 
the best medical centres the full extent of the disease may be unknown [25] and up 
to 2017 it was not identified any fully validated, symptom-based, patient- reported 
questionnaire for endometriosis screening in adult women with potential endome-
triosis [26]. One must think to endometriosis in adolescent girls with family history, 
abnormal characteristics of menstrual cycles with the aim to avoid the structural 
and functional abnormalities progression induced in women’s endometrial genes - 
mainly Hox codes for steroid hormones receptors, ligands, and co-regulators.
The next pages will discuss concepts, theories or hypothesis of potential thera-
peutic options and perspectives for prevention, normalization or restoration the 
endometrial estrogen- progesterone balance, and their receptors in the epithelium 
and stroma, because many years there were recommended ovarian supressing 
drugs, and surgery.
2. Endometrial phenotypes in endometriosis
The interest for diagnosis and therapeutic success connected to side effects, 
limitations and failure rate of different classes of medication, and high risks of 
recurrence after surgery or medication discontinuation imposed the analysis  
of endometrium phenotypes, proliferative and differention in vitro capacities of 
stromal cells from ectopic lesions of peritoneum, ovaries, and deeply infiltrating 
endometriosis in comparison to the same structures of normal women, using the 
new techniques as contrast microscopy, immunocytochemistry, functional bioas-
says [27] and RT- qPCR of endometrial genes.
The study of Burney et al. [28] analyzed eutopic and ectopic endometria 
comparative to non ill women, and it was demonstrated a molecular phenotype of 
attenuated progesterone response within eutopic endometrium, from the dysregu-
lation of numerous genes which are progesterone regulated, and the progesterone 
resistant phenotype is more frecquent in ectopic endometrium comparative to 
non-ill cases. This condition is associated to a pro-inflammatory phenotype [29, 30] 
which increases both estrogen dominance, and progesterone resistance. The eutopic 
endometrium of ill women has an attenuate response to P4 because estrogen-
responsive genes are not suppressed in their stromal cells in early secretory phase of 
menstrual cycle comparative to normal [28, 31, 32]. The British and Italian doctors’ 
conclusion [29] was that endometriotic cell lines, and stromal eutopic endometrial 
cells in ill-women are lossing the capacities of differentiation, and respectively of 
deciadualisation, aspects that explain cells capacities for proliferation and survival 
in the ectopic environment, and high infertility/subfertility rates. Deep endome-
triosis appears to be a special type, because predominance of PR less active isoform 
(PR-A) over the full length, due to epigenetic abnormalities affecting PR gene 
transcription, associated to oxidative stress, facts that induce a condition of more 
resistant to size regression upon medical treatments [7].
3.  Concepts on endometrial peculiarities, as a steroid hormones target 
in endometriosis. Estrogen dominance. Progesterone resistance. 
Progesterone attenuance
The efficacy of endometriosis therapies may be improved by dissecting the 
unique molecular properties of eutopic and ectopic endometria compared to normal 
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endometrium. At first glance, the terms “estrogen dominance” and “progesterone 
resistance” appear to describe opposite sides of the same coin [6]. Endometrial 
Progesterone Resistance is described since many years [33] as there are other hor-
mones resistance, being first named as “Pseudocorpus Luteum Insufficiency” [34] 
meaning that endometrium is not able to respond to bioavailable P4 plasma levels 
inbetween normal limits. In non-ill women E2 induces epithelial proliferation to 
build endometrial thickness during the proliferative phase of the menstrual cycle, 
then P4 inhibits E2-induced proliferation and allows stromal cells to begin decidu-
alization during the secretory phase [35] in order to prepare the stroma to become 
receptive to blastocyst invasion during “window of receptivity/implantation” in 
normal, fertile women [36].
3.1 Dysregulation of endometrial steroid hormones receptors in endometriosis
The molecular mechanism triggered by ovarian steroid hormones in endome-
trium is well known: steroid hormones link to specific nuclear (ERα, ERβ; PRA, 
PR-B, with specific ratios between them), cytoplasmic (ERβ), and membrane 
receptors (non- canonical G protein-coupled estrogen receptor (GPER) [37] and 
PGRMC-1 and PGRMC-2), which are able to bind to the promoter of the target 
genes, being up- or down- regulated by their co-activators (SRC-1, SRC-2, SRC-3 
for estrogen receptors- ER) or downstream effectors (TGFβ, Dickkopf-1, retinoic 
acid, c-myc, etc. for progesterone receptors- PRs) [28] and influence endometrial 
cells proliferation and differentiation [38]. Endometrial repair after menstruation, 
proliferation and/or differentiation processes are dysregulated in endometriosis 
when menstrual reflux with endometrial stromal and epithelial glands cells with 
their exosomes migrate, adhere and invade peritoneal surface and/or other ectopic 
sites, associated to waves of inflammation (by systemic and local reactive responses 
to the presence of endometrial debris), neuro- angiogenesis and neuroinflam-
mation, and aberant scar formation through fibrosis and adherences (possible a 
self-protection mechanism for ectopic lesion, as in chronic infections) at every 
ovarian cycle (different from normal endometrium restoration after each menstrual 
cycle). All these events are genetic controlled, epigenetic changed by hyper (for 
PR promoter) or hypomethylation (for ERβ) of DNA steroid hormones receptors 
promoters [39–41]. When the tightly regulated balance of epithelial- stromal P4 
and E2 signaling is lost, P4 resistance and E2 dominance are prone to ensue, as 
in endometriosis [6]. P4 resistance may lead to both increased lesion growth and 
a non-receptive endometrium, and actually one speaks also about progesterone 
attenuated response in eutopic endometrium, which is associated to infertilty/
subfertility. Estrogen dominance, progesterone resistance and progesterone attenu-
ance in the ectopic and eutopic endometrium are explained by the dysregulation 
of estrogen and progesterone receptors their genes (ESR1 and ESR2) [32]; a single 
gene- PRG for PRs) [42] with their micro-RNA (miRNA) –the cells’ critical regula-
tors for development, and physiology, their mis-expression being associated to 
pathology [43].
When dysregulation condition persists it leads to both increased lesion growth 
and progression to a superior stage, and a non-receptive endometrium. P4 acts on 
stromal cells of the normal endometrium, inducing paracrine factor(s), and they 
induce the expression of the enzyme 17β-hydroxysteriod dehydrogenase type 2 
(17β-HSD-2) for metabolization of E2 to estrone (E1), in the epithelial cells, and 
cell proliferation arrest. Excess E2 with Estrogen Dominance, and Progesterone 
Resistance are well documented in ectopic endometrium with aberrant levels 
of ERs and changed ER-α/ ER β ratio, where the genes analyses have proved to 
become an acquired property, through their migration and exposure process to 
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peritoneal environement [5]. ER-α and ER- β have essential roles in establishment 
and progression of ectopic lesions [32]. ERβ is excessively expressed in stromal cells 
of the ectopic lesions, versus non-ill women, fact due to hypomethylation of ERβ 
promoter, which contributes to low ER-α expression in ectopic endometrium [41, 
44]. ERβ protein net -work together with SRC-1 coactivator isoform with which it 
cooperates, may have a cytoplasmic, non-genomic action in endometriosis as Han 
SJ, Jung SY, Wu SP, et al. discovered [44] (Figure 1).
Eutopic endometrium may prove the same endometrial dominance and proges-
terone resistance, but after some years of disesease evolution, being described cases 
with initial progesterone attenuance in eutopic endometrium and progesterone 
resistance in the ectopic sites, usually in deep endometriosis [28]. It is docu-
mented a local increased synthesis of estrogen [45, 46] not a systemic high level 
[47] through the presence of the enzymens (aromatase, and 17β-hydroxysteroid 
dehydrogenase-1, 17β-HSD-1) [48, 49] and a blunted response to progesterone in 
eutopic and ectopic endometrium, P4 serum levels being similar to non- ill women 
[45]. In human and experimental mice the ER-α content may be normal in eutopic 
endometrium, as in non ill women, but ER β are increased in both epithelial and 
stromal endometrial cells of eutopic and ectopic sites, as PRs levels are reduced in 
eutopic endometrium and PRs are lost in ectopic sites [44]. A recent analyses of 
ERs in deep endometriosis revealed that ER-α is a subtype for this condition [50] 
ER-α levels being predictive for symptoms severity, and for responses to treatment 
[51]. Progesterone attenuance of eutopic endometrium is connected to altered 
endometrial receptivity in the “window of receptivity/implantation” and to a 
significant reduction of implantation rate in ill-patients trying in vitro fertiliza-
tion, due to stromal cells impair decidualization proved by a reduction of nearly 
2-fold in IGFBP-1, and of leukemia inhibitory factor (LIF) [52] and to reduction/
dysregulation of P4 target genes during the “window of receptivity/implantation”, 
time when normally, the endometrium is exposed to the highest levels of P4 [53] as 
it is strikingly down-regulated glycodelin- the prototype progesterone-responsive 
gene, in eutopic endometrium of ill-women compared to non-ill [53, 54]. LIF low 
levels are an intrisic glandular dysfunction, induced by the gland-specific transcrip-
tion factor Forkhead box A2 (FOXA2) low level [55, 56] also a P4 gene target. There 
are contradictions on the status of ERs and PRs in ectopic endometrium – an ERs 
increased expression, or others show reduced expression of both ERα and ERβ 
Figure 1. 
Role of ER-β in endometriosis. microRNA levels of steroids in primary stromal cells isolated from endometrium 
and endometriosis (n = 8 patients in each category). Comparable in vivo differences were also observed between 
whole tissues of endometrium and endometriosis Legend: ER: estrogen receptor; PR: progesterone receptor; real 
time-PCR: polymerase chain reaction (adapted from Bulun et al. [45]: open acces).
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[57–59] and lower levels of PRs [5, 60]. The eutopic endometrium has an attenuate 
answer to P4, the isoform PR- B is not expressed in patients’ endometrium, being 
only the isoform PR-A, because progesterone-responsive genes are not deleted in 
eutopic endometrium in comparison to normal women in the early secretory phase 
of cycle [28–32], a normal PR-A/PR-B ratio is very important in endometrial func-
tion. One may consider that the relative differences between studies regarding the 
PR isoforms loss in ectopic and eutopic endometrium may be explained by stage of 
disease, type of lesion and cells, and method of analysis.
Previous studies [32] demonstrated in experimental mice that high levels of 
ERα are driving proliferation, adhesion and angiogenesis in ectopic tissue, and also 
modulate inflammation, and ERβ prevents apoptosis and enhance invasion, prolifer-
ation, adhesion, and inflammation to stimulate the growth of ectopic lesion, so both 
isoforms might sinergistically contribute to regulation of proliferation, adhesion, 
and inflammation in endometriotic lesion. These discrepant findings are explained 
by the differences in study design, patient selection criteria, cycle stage, and endo-
metriosis type and stage. Similar to these contradictory results on endometrial 
steroid hormones receptors is the situation with miRNA indentification by real-time 
quantitative reverse transcription-polymerase chain reaction (real time qRT-PCR) in 
normal endometrium, eutopic and ectopic sites, connected to mi-RNA upregulation 
(over expression) or down regulation (under expression) in eutopic and in different 
ectopic areas (peritoneal, ovarian), and some are “mis-expressed” endometriosis 
[61]. There are differences between authors, with conflicting reports on whether or 
not miRNA expression was influenced by the menstrual cycle phases, endometrial 
cell type, miRNA type, level in ectopic/eutopic tissue, and stage of disease.
3.2  High micro-heterogeneity of endometrial steroid hormones receptors 
signaling in endometriosis
Normal endometrium is containing large quantities of distinct stromal cells 
with abundant estrogen-induced PRs, which influence glandular epithelial cell 
proliferation and differentiation, and protect against carcinogenic transformation, 
when PRA/PRB are in a proper ratio to ensure normal P4 response. PRA and PRB 
are members of a superfamily of almost 50 ligand-activated nuclear transcription 
factors [62]. In-vitro studies suggest that the two PR isoforms differ functionally, 
and that their relative expression in a target cell may determine the nature and 
magnitude of response to P4. The two isoforms are in comparable levels expressed 
in proliferative phase, but in the mid- secretory only PR- B is present in the epithe-
lial glands, PR-A is predominantly present in the stroma throughout the cycle. It is 
a homogeneity in the relative expression in PR-A and PR-B in adjacent cells within 
the same tissue compartment, and a heterogeneity between glands, observed under 
some circumstances in the endometrium functionalis, suggesting that PR isoforms 
down-regulation by P4 is asynchronous, and between the glands of the basalis and 
functionalis of the endometrium implying region specific responses to hormonal 
stimuli [63].
A recent European study on deep endometriosis [64] showed a high variability of 
ERα and PR distribution in the same gland, among distinct glands of the same sample, 
and among distinct patients receiving the same treatment. Luminal epithelial height 
variability was primarily due to epithelial cells heterogeneity in a gland, secondarily 
to the glands randomaly evaluated on the same section, and tertiary to the patient 
category. The heterogeneity of ERα and PR distribution in the same women could 
explain why endocrine treatments are unable to cure deep endometrios. The cause of 
heterogeneity in endometriotic tissues is difficult to be ascertain, one hypothesis being 
the DNA methylation of the steroid hormones [65] or of their promoters [39, 40] or 
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an abnormal proteolysis of steroid hormones chaperons [66]], the co-chaperons are 
required by PR for signaling uterine cycles and implantation [67].
Mice induced endometriosis demonstrated a high inter-animal variation in the 
levels of ERs, PRs, in ectopic endometrium vs. controls; with variable levels by 
almost 100-fold within the same lesion, and with differences between two lesions 
from the same animal [68] aspect called “micro-heterogeneity”. The changes are tis-
sue intrinsic, and some researchers propose that the variable outcomes in hormonal 
therapy for endometriosis could be possibly due to heterogeneity or polymorphism 
in the expression of steroid hormone receptors in the ectopic endometrium [68] or 
in all endometrial locations- eutopic, and ectopic, being known the heterogeneity 
of PRs in glands, and the homogeneity of PR isoforms in stroma of normal human 
endometrium [63] making the magnitude in response, the attenuance, and the 
resistance in response to P4, independently to the serum levels of P4 [69]. This 
intrinsic biologic alteration of eutopic endometrium explains the missing differ-
ences in endometrial thickness, and histology –respectively luteal differentiation, or 
epithelial integrin expression at the lower mid-luteal serum progesterone level (as 
3–4 ng/ml) in programmed cycles of physiological and subphysiological exogenous 
progesterone replacement in GnRH agonist-suppressed healthy volunteers. One 
may consider that these results are an answer to the questions whether the abnor-
malities of eutopic endometrium in early secretory phase suggestive of attenuated 
progesterone response in the transition from proliferative to secretory phase are due 
to lower level of circulation or local bioavailable progesterone or to the changes in 
endometrial transcriptome, with dysregulation of progesterone- regulated genes.
3.3  Nuclear receptor coregulators in the modulation of progesterone and 
estrogen signaling in endometriosis
Endocrinologic literature presents different series of nuclear receptors coregula-
tors,- proteins that intervene to modify chromatin structure and regulate large-scale 
gene transcription programs by forming large complexes with the nuclear receptors 
of the target cells [70]. In the female genital tract the PRG and ESR1 are critically 
regulated by a family of regulatory proteins named steroid receptor coactivators 
(SRCs) - SRC-1, SRC-2, and SRC-3, the first nuclear receptors coregulators are 
involved in the balance between E2 and P4 in human endometrium. SRC-1 down 
regulates P4 target genes in the epithelium, and up regulates them in the stroma; 
SRC-2 is necessary for human endometrial stromal cells decidualisation [71] for 
P4 signaling and for ESR1 signaling; the transcriptomic analysis revealed that 50% 
of SRC-2-regulated genes are also regulated by P4 [72] and it is critical for murine 
uterine function; ablation of SRC-2 induces partial loss of decidualisation and 
infertility, and both SRCs ablation induces complete loss of decidualisation [73, 74].
4.  Potential therapeutic options to maintain/restore endometrial normal 
estrogen-progesterone signaling in endometriosis
Presently pharmacotherapy mainly with hormones (Hormone Therapy- HT) 
and surgery are two cornerstones in endometriosis management. Surgery with his-
tological confirmation of ectopic endometrial glands and stroma remains the gold 
standard for diagnosis [75, 76] surgery being generally reserved for patients who fail 
medical therapy, or who desire pregnancy, being usually performed by laparoscopy 
[77, 78]. Surgery is able to eliminate visible endometriotic lesions, without the cure 
of the disease [79], and majority of drugs are symptomatic, not cytoreductive [80]. 
Yet it is not known if surgery itself may be incomplete (i.e., microscopic disease) 
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or if other factors, such as aberrant PRs expression of the eutopic endometrium 
influences recurrence [60] connected to the eutopic endimetrium transcriptome 
changes compared to non-ill women, indicating abnormalities that predispose to 
new implants in extrauterine locations after surgical excision of ectopic lesions 
[81]. Recurrence rate after surgery or medication discontinuation was recorded up 
to 45% after 5 years [82] and recently one discusses the translation from adjuvant 
therapy to tertiary endometriosis prevention in postoperative medical care [83]. 
The moment of medical therapy associated to surgery- before, after, or both before 
and after surgery is much analyzed, to maximize treatment response, but literature 
data is still inconclusive [84]. The HT goal is to induce atrophy of endometriotic 
lesions, even if one missis the ability to predict which medication each individual 
patient will respond to, being many attempts to find one or more predictive mark-
ers [85] to score HT, as it is the immunohistochemical Histo (H) -score on the PRs 
status, and CYP19A1 expression for the response to progestins, respectively for the 
need to block estrogen signaling [60]. The high H-score for PRs was proposed to 
be >80 (associated with 100% positive predictive value), and the low H-score ≤ 5 
(associated to 94% negative predictive value), with some authors’ comments 
regarding H-score usage: the score is useful for ectopic endometrium response to 
progestin- based therapy, not for eutopic endometrium, because the lack of score’s 
correlation to eutopic endometrium. It is recommend to score PRs in the excised 
ectopic tissues, and to determine the reason for progesterone/progestins/COCs 
failure. When adhesions/fibrosis are predominant it is sure the non-response to 
HT, but some PRs expression may indicate an insufficient dosage of progestin or 
noncompliance with therapy (i.e., inability to tolerate side effects), and for cases 
with low H-score, patients being PR resistant, it is advised to avoid progestins after 
surgery in favor of GnRH agonists or GnRH antagonists [86, 87], danazol- rarely 
used actually, or aromatase inhibitors.
Actual medical therapies allow suppression of endometriotic lesions, women 
require long term treatment [79] to maintain the benefits, to avoid recurrences, 
being recognized high rate relapse even after surgery. After surgery one must 
continue HT with contraceptive pills, or IUD [88] with the aim to preserve ovarian 
follicles reserve, and because ovarian aging, to try spontaneous pregnancy or ART.
Individual genetic characteristics can affect the bioavailability and pharmaco-
dynamics of HT, mainly estrogen dominance and P4 resistance/attenuance, and, 
hence, explain part of the variability in the therapeutic response, as it is the poly-
morphism of CYP3A4/5 involved in levonorgestrel metabolism [89].
One can respond to therapeutic wishes by timing progesterone/progestins 
administration, and by moving from pure hormonal therapy to drug combination, 
or to novel molecules capable to restore the various homeostatic disrupted mecham-
nisms by disease. A number of potential therapeutics are currently in pre-clinical or 
early clinical studies, fact which may alter further treatment strategies.
4.1 Progesterone/progestins therapy
Kistner [90] was first who postulated that decidualisation observed during preg-
nancy might cause necrosis, and the consequent elimination of superficial ectopic 
implants, and this was the logical reasoning for progesterone recommendation, 
and use to control endometriosis. During pregnancy on assists at ovarian functions 
suppression, fact that is mimicised by HT in endometriosis [91]. After Kistner RW 
first initiave in the years 1960, there were used progestins, which are inducing a 
pseudo-pregnancy endometrial aspect or endometrial atrophy at microscopy [92]. 
The progestins are synthetic different derivates, such as C-21 progesterone deri-
vates (medroxyprogesterone acetate, MPA, and depot MPA, and dydrogesterone, 
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(DYD- a semisyntethic progesterone derivate), or C-19 nortestosterone derivates 
(levonorgestrel, norethisterone, lynestrenol, desogestrel, and dienogest), or the 
19-norprogesterone derivates without androgenic activity; nomegestrol acetate 
– (NOMAC) has a similar anti-gonadotropic activity compared to the 19-nortestos-
terone derivates with androgenic activity, norethisterone acetate (NETA) [93] and 
a separate class with drospirenone, the unique progestin [94]. The COCs with the 
synthetic ethinyl-estradiol (20, 30 μg/pill) plus one of the previously mentioned 
progestins represent a very important cathegory in the control of eutopic and 
ectopic endometria from intrinsic abnormal steroids signaling [95]. One must keep 
in mind the Japanese oppinion [96] that concurrent estrogen action is essential 
for maximal progestin effect in COC, fact controverted by some studies regarding 
patients satisfaction on pain alleviation in endometriosis, explained by summer-
izing endogenous estrogen local levels in ectopic endometrium to that of pills [97] 
but estrogen priming may be necessary to induce PR in endometriotic lesions [96, 
98] as progesterone usually actions on estrogen primed tissue. Progesterone and 
progestins, alone or in association to a synthetic estrogen are considered first line 
therapy in endometriosis. The positive response to progestins alone or combined 
estrogen- progestins may induce only partial improvement, the ectopic sites are not 
eliminated or some patients do not respond at all [99] being recognized only the 
quiescence of lesions, at best [100] and when first line therapy fails – in one- third 
of women because progesterone resistance [79] or it is contraindicated, or it is not 
tolerated one recommends Gonadotropin-Releasing Hormone (GnRH) agonists, 
GnRH antagonists, and aromatase inhibitors being used in cases refractory to other 
therapy. Up to 2021 it was published a single RCT on COCs in endometriosis [101] as 
Donnez and Dolman [79] mentionned in the last European review. It is described a 
statistically significant, though modest, improvement in dysmenorrhea with OCPs 
given for four months compared to placebo, and a lack of any beneficial effect of 
OCPs on non-menstrual pelvic pain and dyspareunia, being appreciated the studies 
failure to report data on their efficacy according to lesion phenotype [102, 103].
Patients present variable responses to progesterone/progestins, according to their 
pharmakinetics, to their capacities to reacts to medication (genes, receptors for E2, 
P4), to metabolize progesterone/progestins connected to their levels of N-Acetyl 
transferases, associated to drug kinetics control by acetylating and converting active 
forms into inactive metabolites, to their cytochrome P450 3A (CYP3A) system- one 
of the most known pathway in steroid hormones metabolism,and P450 3A polymor-
phism is not precisely known in endometrial patgology [89].
4.1.1 “Old” hormone therapies still active in endometriosis
During the long time of progestins usage it was reported a good rate of patient 
adherence and satisfaction [104, 105]. There are few direct comparisons between 
different types of progestins in endometriosis clinical studies, with the scarce 
evidence suggesting that when given by the same route and the same regimen, the 
effectiveness may be similar [7]. By binding to PRs, progesterone/the synthetic 
compounds, administrated orally or by non conventional routes (vaginal [106], 
intrauterine [107]) induce inhibition of estrogen synthesis through down regulation 
of ERs [64] and of steroidogenic enzymes in endometrial stromal cells, either by 
up regulation of the oxidative 17β-HSD type 2, which transforms E2 to E1 [108], 
being triggered by retinoic acid [109] or by reduction of 17β-HSD type 1 expression, 
and activity, − as was proved specially for MPA, DYD, dienogest [108, 110] which 
induces the inhibition of aromatase expression with a low local estrogen production 
in immortalized human endometrial epithelial cells [111] with inhibition of eutopic 
and endometriotic cells proliferation, and reducing cells survival by apoptosis 
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induction [112] with limitation of local angiogenesis and neurogenesis (proved with 
the CD31- a neurovascularisation marker), and linking all these mechanisms, the 
attenuation of the immune-inflammatory response (proved to be more accentuated 
on new progestins as drospirenone by its effects on inflammatory cytokines - VEGF, 
and nerve growth factor) [113] so progesterone/progestins change the morphology 
of endometrium- ectopic and eutopic with reduction of lesion sizes, but with net 
differences in their response to these drugs, as experimental and clinical studies 
demonstrated [7, 114], stages III- IV are not responding. Longitudinal assess-
ment of endometrial morphology has demonstrated that the histology aspects are 
changing in time: initially one registers secretory differentiation, and after several 
cycles through ERs down- regulation one registers atrophy with tubular glands, 
weak secretory vacuolation, and stroma low cellular density [115]. Usually one 
recommends a HT for long term duration, short term therapy being insufficient 
to obtain the wanted effects, even with dienogest, − which in a short term therapy 
demonstrated a high frequency of decidualisation and a tendency of inflammation 
reduction, but it was not able to induce differences comparable to non- treated cases 
in terms of necrosis, glandular atrophy and angiogenesis [116] (Table 1).
4.1.2  Timing progesterone/progestins for preventing progesterone attenuance and 
progesterone resistance in endometriosis
The discussion on administration of progesterone from early ages of reproduc-
tive period, just to permit P4 to stop endometriosis progression, inflammation, 
and angiogenesis, by maintainance of ERs, PRs normal ratios in epithelial glands 
and stroma, is supported by Li et al. study [114] at University of Illinois at Urbana-
Champaign, (USA). Endometriosis was induced in two immunocompetent mice 
groups, differently maintained afterwards: one group with E2, and the second 
group with E2 and P4 subcutaneously, at every 4 days beginning at 4 days before 
lesion induction (pre- P4 treatment). The endometriosis-like islands were very 
quickly developed, with different numbers, aspects and sizes according to steroids 
administrated- after E2 alone there were yellow, more numerous, larger, with 
abundant blood vessels and extensive adhesions; after E2 plus P4 were white, 
smaller, non-vascular, with loose attachment. The microscopy (H&E, special 
biomarkers, IHC for ER, PR, their genes) have shown marked differences regard-
ing mitotic activity (Ki-67 reduction), glandular secretion, endothelial cells and 
angiogenesis (CD31 increased when was added P4 before induced endometriosis). 
Another peculiar aspect in the treated group with E2 plus P4 are the inflammatory 
response changes - first an increase, and later a reduction of inflammatory cells, and 
changes of their type in endometriosis-like tissues, with similarities between groups 
in the first 16 days, and a dramatically changed aspect of inflammation after 24 days 
from induced endometriosis, such as suppressed production of pro-inflammatory 
cytokines, and infiltration of immune cells in ectopic sites. The authors debated 
the P4 action to alleviate lesion outgrowth and to maintain ERα and PR expression 
• P4 restricts expansion of the ectopic lesions by inhibiting endometrial cell proliferation, and 
neovascularization
• P4 suppresses E2-dependent inflammatory responses in the ectopic lesions
• P4 maintaines ERα/PR-mediated signaling; their loss in the ectopic lesions leads to resistance to P4 
therapy if the treatment is postinduction of lesion
Table 1. 
Progesterone alleviates endometriosis, induced in the peritoneal cavities of femele immunecompetent mouse, 
maintained with estrogen if administered before illness induction (from Li et al. [114]).
11
Potential Therapeutic Options and Perspectives for Alleviation of Endometrial Estrogen…
DOI: http://dx.doi.org/10.5772/intechopen.100039
when P4 is administrated before lesion induction. The use of RT- qPCR permited 
the endometrial genes assessment in eutopic and ectopic endometria, showing a 
progressive down-regulation of miRNA expression corresponding to ESR1, PRs 
and PR-stromal targets Hand2 and Hoxa-10 with time of disease progression, and 
in contrast a gradually increase of ESR2 miRNA, parallel to increased expression of 
ESR1, PRs, and HOXA 10 in ectopic lesions, while Hand2 expression remained sup-
pressed when P4 was administered before lesion induction (PreP4). The P4 inhibi-
tory effect was not observerd when P4 was started at 4 days after endometriosis 
induction (Post-P4). The study results clearly indicate that the loss of PR-mediated 
signaling components is a major causal factor for the P4 resistance existing in mice 
with endometriosis. The conclusion is that progesterone supplementation from 
early moments of disease, when PRs are still present can preserve steroid respon-
siveness and ameliorate E2-dependent disease progression, but when at later stage, 
P4 supplementation has minimum effects, because of PRs absence. The hope is that 
if PRs women’s loss is progressive after disease onset, the add of P4/progestins may 
action with the wanted effects.
4.1.3  Not all progestins are equal in restoring estrogen- progesterone balance in 
endometriosis. New trends-dienogest
If there were questions if progestins are all equaly capable of acting on endo-
metriosis lesions to induce apoptosis, or to inhibit cell proliferation, adhesion, 
invasiveness, angiogenesis/neuroangiogenesis, and inflammation, actually one 
knows their different actions and effects, according to their biochemical structure, 
and cross effects on glucocorticoid, mineralocorticoid and androgen receptors 
[117]. In the last 20 years, starting with the Japanese experiments [118] on rats 
induced- endometriosis, the progestin dienogest (DNG) was much analyzed in 
Japon, USA, Europe (The European Clinical Study Program) [119] in order to avoid 
progesterone resistance or progesterone attenuance, by reducing estrogen deleteri-
ous effects on endometrium- normal, eutopic and ectopic increasing PRs expres-
sion and decreasing proinflammatory cytokines, and the necessity of “add back” 
therapy imposed by GhRh agonists [120, 121] as it will be further discussed. It was 
demonstrated that DNG 2 mg/day (once/day in Europe, and 1 mg twice/day in 
Japon) [120] after 24–52 weeks of administration reduces lesions size, [122] without 
changing bleeding pattern [123] and with a good score regarding chronic pelvic 
pains [120]. Because it was proved an in vitro dose-dependent inhibition of human 
endometrial stomal cells proliferation together with morphological and functional 
changes [124], an Italian clinical study on 20 cases of endometriosis [125] had 
evaluated doses of 20 mg/day effects, for 24 weeks, with no comparative study-
group, and showed no clinically significant effects on hemostasis, haematologic 
parameters, thyroid and adrenal, liver functions, glucose and lipid metabolism, or 
electrolyte balance, with maintainance of mean high-density lipoprotein-3 choles-
terol from the baseline.
The morphological studies reported inhibition of endometrial cells prolifera-
tion, by down-regulation of ESR2/ESR1 ratio [126] and aromatase expression [127] 
with local estrogen synthesis reduction, and the inhibition of human endometrial 
stomal cells proliferation, together with functional changes, as it is prolactin syn-
thesis- a typical marker for decidualisation [124] and the association of increased 
apoptosis in endometriotic lesions [128]. DNG increases the PR-B/PR-A ratio in 
ovarian endometriosis [126] and down-regulates the expression of CYP19A1, and 
inflammatory, and neuroangiogenesis factors through PR- A and B- isoforms [129]. 
Some studies have revealed that DNG reverses some alterations of the immune sys-
tem by increasing natural killer cells in the peritoneal fluid, and spleen, parallel to 
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the decrease of peritoneal fluid cellular content, and lower peritoneal macrophages 
synthesis of inflammatory cytokine IL-1β [118], and inhibits IL-1β release by the 
endometriotic epithelial cells [130].
4.1.4  Extended regimen of continuous combined hormonal contraceptives in 
endometriosis
The continuous regimen or extended cycle vs. cyclic use of combined hormonal 
contraceptives was first proposed by Loudon [131] in a family planning clinic from 
Ediburgh (UK) by skipping the tablet-free interval of 7 or 4 days. The innitial pro-
posed non traditional regimen was with 84 active pill with etyhil estradiol 50 μg 
plus linestrenol 250 μg /day and 7 days free, and it obtained a great adherence in 
women suffering of endometriosis, according to suppression of withdrawal bleed-
ing, and inducing atrophy in ectopic and eutopic endometrium, as it is recognized 
by Cochrane Database Syst Rev., 2014 [132]. The regimen was recommended  
with levonorgestrel – LNG (90 or 100 μg/day), drospirenone- DRS (3 mg/day)  
[133, 134] desogestrel (150 μg/day) [135], NETA (1000 μg/day) [136], and recently 
dienogest (2 mg/day) [137] as progestins, associated to 20 or 30 μg/day of ethinyl 
estradiol. The regimen of ethinyl estradiol 20 μg plus LNG 90 μg/day was reported 
for 364 days at Eastern Virginia Medical School, Norfolk (USA) [138] and in Italy 
during 6 months with ethinyl estradiol 20 μg plus LNG 100 μg/day [139], or during 
3 to 6 months in Germany, Frankfurt University [140, 141], and recently the Italian 
prospective open label study [137] analyzed ethinyl estradiol 30 μg/day plus dieno-
gest 2 mg/day in a continuous regimen vs. 21/7 to assess quality of life and sexual 
function in women with endometriosis. The pharmaceutical industry created some 
drugs combinating ethinyl estradiol 30 μg/LNG 150 mg/day for 84 days plus 7 days 
placebo, or the combination of ethinyl estradiol 30 μg/LNG 150 mg/day for 84 days 
plus ethinyl estradiol 10 μg/day for 10 days, or of ethinyl estradiol 20 μg/LNG 
150 mg/day for 84 days plus ethinyl estradiol 10 μg/day for 10 days [142] after the 
concept called “tricycle regimen” or “tricycling”, first named so in Sweden in 1993 
very easy to be followed, and very well appreciated by users [135].
The literature describes some attempts to short free hormones interval for the 
reduction of hormone withdrawal symptoms, as pelvic pains, headaches [143] and 
this regimen used LNG, norethindrone (1 mg/day), desogestrel, and norgestimate 
with ethinyl estradiol 35 μg or less/day. All these attempts were followed by better 
results of pelvic pain control, but after a longer duration of administration (as after 
6 months of norethindrone).
One must consider the tricycle regimen of contraceptives in adolescents suf-
fering of menorrhagia, dysmenorrhea, or with family history of endometriosis, in 
order to reduce the concerns of a future progress of an eventually later diagnosed 
endometriosis, existing already findings on this cathegory of women, at the 
Department of Adolescent Medicine of the University of Pitsburg (USA), with a 
significant ovarian suppression, endometrial atrophy, no metabolic change, and 
adolescents safety [144]. At this study one must add a recent one [145] sustaining 
that women who used the new generation of COC or only progestins have lower 
circulatory inflammatory biomarkers [IL-6, sTNFR2 (soluble tumor necrosis factor 
α receptor 2), and in a lower degree C-reactive protein] similar to the effect of a 
higher number of lifetime ovulatory years. The presence of progesterone after 
ovulation, the new generation of COCs, and the effects of progestins can be the 
explanation for the benefits in reducing systemic inflammation; being considered 
that chronic inflammation reduces ovulation rate in premenopausal women, and 
ovulation and menstruation increase local inflammation.
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There are recent reviews on the comparison of flexible/extended COCs to cyclic 
COC use in endometriosis, published in 2018 in USA (on dysmenorhheea, non- pel-
vic pains, dyspareunia [146]), or in Europe [147] and the systematic review (2019) 
of only 8 RTC published between 1934 and 2018 (of a total 743 studies) on dysmen-
orrheea [148] and in 2021 [79]. It is shown a statistically significant, though modest, 
improvement in dysmenorrhea - a reduction of 50% when COCs were given for 
four months compared to placebo [147] and a shorter duration of only 4 days of the 
pains, with conflicting results on interference with daily activity, pain severity, and 
pain reccurence [148].
4.1.5  Different routes of administration for progesterone/progestins to increase 
positive effects in alleviation progesterone attenuation/resistance and estrogen 
dominance
Since many years one discusses non conventional routes for drug administra-
tion in order to avoid the second liver passage, and to increase bioavailable active 
substance where is necessary. Vaginal route for progesterone and medicated intra-
uterine devices are most analyzed for their beneficial endometrial effects, without 
or with less systemic effects of progesterone/progestins.
4.1.5.1 Vaginal route for micronized progesterone
Natural Progesterone has far more anti- inflammatory properties, fewer side 
effects, is very versatile in how it can be used, and the micronization of P4 is very 
important, and the oral micronized progesterone capsules were re-directed to be 
used vaginally [149]. Micronized P4 has a more selective effect on PRs, and results 
in less interaction with androgenic and mineral-corticoid receptors compared with 
progestins.
The vaginal route for P4 was proposed since many years ago [150] but the new 
hypothesis regarding the higher endometrial P4 levels than that obtained after 
intravenous administration was presented by Cicinelli and de Ziegler [151]. This 
phenomenon of preferential uterine distribution after vaginal administration was 
named “first uterine pass effect” [38] or “uterine specificity of vaginal proges-
terone” [152]. The high uterine level of P4 vaginally administered is explained by 
various putative modes of transport including direct diffusion through tissue, intra-
cervical aspiration, absorption into the venous or lymphatic circulatory systems 
and countercurrent vascular exchange with diffusion from utero-vaginal veins/
lymphvessels to arteries. While the serum P4 concentration is often low or “sub-
physiological”, endometrial effects show in most cases clear and complete secretory 
changes, or pseudodecidual aspects, or atrophy after long duration of therapy 
[153]. In USA at Brigham and Women’s Hospital [154] one recommends vaginal gel, 
cream, or suppositories, in a higher dosage for endometriosis control than that for 
replacement therapy recommanded in menopause, such as 300 mg twice a day for 
minimum 3 months, then 300 mg at bed-time.
4.1.5.2 Medicated intrauterine systems to restore estrogen-progesterone balance
The direct application of progesterone or a progestin (usually LNG), or of a 
SPRM (ulipristal acetate was proposed) was another potential option to control 
estrogen dominance in eutopic endometrium, for avoidance irregular effects 
of systemic progestins, considering a consistent inhibition of ERs expression in 
eutopic endometrium [107, 155] with pain reduction, or to avoid pain relapse in 
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postoperative period, and a total patients’ satisfaction when compared to their 
attention for daily pills intake [156].
4.2  New therapeutic strategies to restore estrogen-progesterone endometrial 
balance in endometriosis. Selective estrogen receptor modulators (SERMs). 
Selective progesterone receptor modulators (SPRMs)
Medical literature presents under the name of selective estrogen receptors 
modulators (SERMs) a relative new cathegory of drugs aimed to target down- 
regulation of E2 signaling, by a direct binding to ERs in a tissue specific manner 
[91]. The studies on rat induced endometriosis [157] have shown the reduction of 
endometriotic lesions by down-regulation of ESR1 and cell proliferation by baze-
doxifene or by raloxifene, but in a RCT on administration of raloxifene (180 mg/
day) after laparoscopically apparent complete excision of ectopic lesions, it was 
recorded a shortly time for chronic pain relapse with raloxifene vs. placebo, but 
without recurrence of endometriotic lesions at the second laparoscopy [158] and 
these results have reduced the enthusiasm for first and second generation of SERMs 
in endometriosis. The third generation of SERMs administration - basedeoxifene, 
reduced glands size and number of ectopic sites in mice [159].
The selective progesterone receptor modulators (SPRMs) are known since long 
time, with the antiprogesterone representative RU 436 or mifepristone. SPRMs 
were proposed to treat unresponsive cases to progestin treatment, due to progester-
one resistance dilemma [160] connected to their direct interaction to progesterone 
receptors, in order to reduce estrogen- induced cells proliferation and prosta-
glandins production [161]. Two old multicentres trials on mifepristone showed 
its efficacy in the endometriosis chronic pain control, with lesions size reduction, 
although results are mixed [162, 163].
Ulipristal acetate suppressed ectopic endometrium induced in mice, with slow 
reappearance after discontinuation [100]. After many discussions on the promising 
evidence of inhibiting human endometrial cell proliferation in vivo [164] and on the 
so-called progesterone receptor modulator-associated endometrial changes (PAEC) 
recorded after 6 months of therapy, which is reversible after ulipristal discontinu-
ation [164] the liver life threatening complications induced the discontinuation of 
the study on endometriosis effects [165].
Per global these so called “new” classes of molecules with selective receptors of 
steroid hormones modulation objectives did not covered the expections in endo-
metriosis, according to women pathologic condition progressively induced on their 
steroid hormones receptors dysregulation/loss.
4.3  New potential therapeutic perspectives: A combination therapy 
using agonist of ERβ and the SRC-1 isoform as the next generation of 
endometriosis therapy to restore estrogen-progesterone signaling balance
Long duration of systemic hypoestrogenism may affect brain, heart, and bones, 
in young women, and for non responders to first line therapy mentionned above, 
long term medication with GnRH agonists/ antagonists or aromatase inhibitors can-
not be recommended, fact that imposed more researches to try to improve estrogen 
dominance/progesterone resistance, to stop ectopic tissue growth and disease stage 
progression with chronic pelvic pains, and infertility. These aims were objectives at 
the Bayllor College of Medicine, Houston (USA) where it was proposed a combina-
tion therapy using an agonist of ER β and the steroid receptor coactivator-1 (SRC 1) 
isoform as the next generation of endometriosis therapy – Han et al. [44] (Figure 2).
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The combination of ERβ- selective agonist and SRC-1 is based on the significant 
supressive effect of PHTPP on ectopic lesion growth by inhibiting ERβ activity 
in mice induced endometriosis [166] associated to minimum side effects on ERα, 
without influences on eutopic endometrium or negative influences on mice fertility. 
SRC-1 is considered a PR co-activator, and indirectly through it, ERβ may impair 
PR-mediated signaling in the ectopic lesions, because actually it is no evidence 
available to show that PR could potentially interact directly with ERβ [167]. These 
drivers combination allows marked suppression of ectopic lesion growth compared 
with either individual agents alone, both demonstrating essential roles in early 
stages of disease pathogenesis [168] specially on apoptosis modulation and inflam-
mation reduction.
4.4 Potential therapeutic options for estrogen dominance control
Several medical treatments for endometriosis directly aim to reduce E2 pro-
duction or action in order to mitigate E2 dominant conditions, and actually one 
discusses GhRh agonists, and the new class of GhRh antagonists. These therapies 
are efficient in cases wishing to conceive, and for the control of chronic pelvic 
pains- menstrual and non-menstrual [169] but associated hypoestrogenism is cause 
of many health concerns, requiring hormone “add-back” for long term use [91]. 
Numerous studies included in the Cochrane Data Base Systematic Review (2003) 
[170] revealed since long time that these effects limit the duration of treatment, 
which cannot be administered without “add back”/hormone-replacement therapy 
[171] and treatment cannot be dose-adjusted to alleviate the side effects - Practice 
Committee of the American Society for Reproductive Medicine (2014) [172].
The recent history of HT for estrogen dominance and progesterone resistance in 
endometriosis shows that the “old” injectable depot MPA, which can decrease ESR1 
and ESR2 while increasing PR-A and PR-B in the eutopic and ectopic endometria 
[173] has equivalent efficacy to leuprolide- a GnRH agonist, in reducing pain, but 
with less adverse hypoestrogenic effects on bone density [174].
4.4.1 GnRH agonists. GnRH antagonists
Injectable GnRH agonists (leuprolide, diferelin, nafarelin) are normally second-
line treatments. Which decrease hormone levels by down-regulating the pituitary 
through negative feedback mechanisms [91] and indirectly they favor an endo-
metrial complete silenced hormonal milieu, on the bases of estrogen dominance 
concept. GnRH agonists have been shown to be effective in reducing endometriosis-
related pain [175] with adverse effects – hot flushes, bone mineral density loss, or 
coronary heart disease, headaches due to a hypoestrogenic state, requiring hormone 
Figure 2. 
Hypothesis of Bulun SE, et al. on hypomethylation of ERβ promoter in endometriotic stromal cells 
vs. hypermethylation, which suppresses the promoter expression in normal endometrium by blocking 
transcriptional complex including co-activators of ER- β (adapted from Bulun et al. [45]: open acces).
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“add-back” [91]. It was reported a mean percent decrease from baseline in bone 
mineral density at the lumbar spine of 3.2% at 6 months, and of 6.3% at 12 months 
after leuprolide alone, and these side effects were associated with rates of discon-
tinuation by 6% because hot flushed, and 8% because of emotional changes [171].
GnRH antagonists, known since long time [176] were in last 10 years under 
investigation for endometriosis treatment in USA, and Europe according to their 
capacity to downregulate gonadotropins, without flare-ups like GnRH agonists 
because they rapidly and directly compete for GnRH receptors [177] and the oral 
administration is another benefit. Their mechanism of action is different to that 
of GnRH agonists. After an initial stimulatory phase desensitize GnRH receptors 
in the pituitary, causing a subsequently depletion of pituitary gonadotropins and 
full suppression of E2 to levels that are equivalent to those associated with bilateral 
oophorectomy [178].
Based on Barbieri RL (1992)” estrogen threshold hypothesis” [179] the 2 large 
multicenters RCTs (Australia, Brazil, Canada, New Zeeland, Poland, USA) [177] 
have concluded that the new oral Elagolix, a nonpeptide GnRH antagonist, in 2 dif-
ferent doses (one with Elagolix 150 mg/day, and the other RCT with Elagolix 100 mg 
twice/day) significantly lower scores for dysmenorrhea and non-menstrual pelvic 
pain than placebo after 3 and respectively 6 months of treatment, and dyspareunia at 
3 months, with significantly better results in cases on 200 mg/day with respect to the 
use of rescue analgesic agents at 3 months and 6 months, dyspareunia at 3 months, 
and rescue opioid use at 3 months less than did those receiving placebo. The dysmen-
orrhea control was better than that of non-menstrual pelvic pains, dysmenorrhea is 
mostly dependent on cyclic changes in ovarian hormones, whereas the mechanism of 
non-menstrual pelvic pain are considered more complex [180]. The results allowed 
the researchers to consider that complete estrogen supression may not be needed to 
controll endometriosis- associated pain, and estrogen may be adjusted to a level that 
is adequate to control pain with minimum hypoestrogenic effects (hot flushes, bone 
mineral density, lipid levels), more frequently claimed in the higher dosage, similar 
to those induced by GnRH agonists. Elagolix was associated with an antiproliferative 
effect at each dose, and with endometrial atrophy at higher dose, which was consis-
tent with decreases in endometrial thickness at that dose, but there were considered 
some limits of the study, as time since endometriosis first surgical diagnosis (in 
between 10 years), short duration (6 months) of drugs administration. Elagolix did 
not completely suppress ovulation at either of the two doses [181] being recorded 
pregnancies, even if patients were recommended to use non – hormonal contracep-
tive methods during trials. Presently one waits the published results of a phase 3 
multicenters RCT in Eastern European countries on an daily oral combination of 
GnRH antagonist (relugolix) with low doses of estradiol and norethindrone acetate 
regarding endometrial histology, and endometriosis associated chronic pain, and 
side effects in comparison to the 4 weeks injectable leuprolide.
4.4.2 Aromatase inhibitors
Aromatase inhibitors (AI), anastrozole and letrozole - the most known deri-
vates, were destinated for control of local E2 levels in many pathologies, and in 
endometriosis they induce regression of peritoneal lesion size, in a higher degree 
than MPA [182] by reducing androgen aromatization into estrogens, both in adipose 
tissue and within endometriotic sites. These drugs are inhibiting endometrial 
progenitor cells migration to ectopic sites [183], and by increasing apoptosis, and 
diminishing endometrial VEGF and PGE2 in a mouse model [184] they reduce 
chronic pelvic pains. AI have significant adverse effects like irregular bleeding, and 
joint pains [185].
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AI action is explained by the promotion of pituitary gonadotropin hormones 
release, with consequent ovarian stimulation; therefore, they must be combined 
with a progestin or other method of gonadotropin inhibition to treat endometriosis 
in premenopausal women [186]. There was compared the association of letrozole 
(2,5 mg/day) to NETA (2,5 mg/day) vs. NETA (2,5 mg/day) alone, and the Italian 
open-label study proved a better control for pain and dyspareunia of the drugs 
association in rectovaginal endometriosis [187] with a better sizes reduction of 
rectovaginal nodules [188] and of endometrotic ovarian cysts [189]. The effect of 
the combination of a progestin to an AI is not lasting after termination of HT, so 
Reis et al. [7] in their published review on progesterone ligands consider letrozole 
as a second therapeutic- line for selected patients, who fail to respond to first line 
HT- progesterone/progestins.
5.  Potential therapeutic perspectives to restore the estrogen-progesterone 
receptors balance in endometriosis
The dysregulation of ER and PR in endometrial glandular epithelium and 
stroma is for sure a pathological mechanism involved in eutopic and ectopic endo-
metrium in women suffering of endometriosis, a disease with onset during embryo-
fetal life, and long time duration, sometimes up to death. The prevention and the 
attemps to maintain or restore the ERα/ERβ, and PR-A/PR-B through their normal 
genes is one of new potential contemporary therapeutic options.
5.1  Genetic/epigenetic interventions in dysregulated endometrial progesterone 
responses in endometriosis
Progesterone resistance in endometriosis has genetic causes as PRs gene poly-
morphisms, altered microRNA expression, and epigenetic changes of PRs and their 
targets. A consequence of impaired progesterone action is that hormonal therapy 
is rendered ineffective for a subset of women with endometriosis. Environmental 
toxins as dioxin may play a role in the genesis of endometriosis by permitting an 
inflammatory milieu.
5.1.1  Progesterone responsive genes methylation: a cause of a dysregulated 
progesterone response
The studies at Yale University, New Haven, Connecticut (USA) using RT-qPCR 
for assessment of endometrial genes in mice induced endometriosis compared 
to normal mice [190] have demonstrated the silencing or inhibition of P4 target 
HOX genes (HOXA 10/HOXA 11, known also as genes of receptivity) by promoter 
hypermethylation - an epigenetic mechanism, which favorizes lack of menstrual 
cycle variation of PRs distribution, which is proper in normal menstruated women, 
and this is appreciated as a partial explanation for the refractoriness of some endo-
metriotic lesions to progesterone/progestin therapy [7, 191]. Altered PRs expres-
sion or diminished activity may lead to attenuated or dysregulated P4 response in 
ectopic endometrium, and decreased expression of P4 responsive genes including 
HOX genes in the eutopic endometrium. Cakmak and Taylor [191] and Lee et al. 
[190] concluded that normal endometrium placed in an ectopic location, in order 
to create experimental endometriosis led to characteristic changes in gene expres-
sion of eutopic endometrium, fact that was previously observed regrading stromal 
stem cells migration to ectopic sites, without this genetic/epigenetic explanation, 
and it was controverted. These data were suggestive for the existence of a signal 
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conduction pathway from endometriosis that alters endometrial gene expression 
through altered Pgr signaling and epigenetic programming. The relatively per-
manent nature of methylation may explain the widespread failure of HT [7]. One 
discusses about promoters methylation, being controversies if both PRs promoters 
are methylated, discovering only PR-B methylation, not PR-A [39] or both PRs 
promoters [192] or DNA methylation of the CG- islands in PR promoter, and its 
gene HOXA 10 [114] as there are controversions regarding ERs genes (ESR-1 and 
ESR-2), being hypomethylated CpG island at the ESR2 promoter region,- involved 
in primary mechanism responsible for differential expression of ESR2, discovered 
to be increased in ectopic and eutopic endometria [40] while other study from 
Brazil [192] denies their methylation in eutopic and ectopic endometria.
5.1.2  DNA methylation inhibitor: a new therapeutic perspective/challenge to 
restore PR-mediated signaling molecules in endometriosis
The women’s ectopic and eutopic endometrial progressive loss of PRs and ERα/
PR-mediated signaling in the developing ectopic lesions during 7 to 12 years from 
histologic disease’s onset to clinical symptoms/signs permits to health care providers 
to intervene in the epigenetic regulation therapeutic control.
The animal studies at the University of Illinois at Urbana-Champaign (USA) 
[114] have shown that a DNA methyltransferase (DNMT) inhibitor, such as 
Decitabine (DAC, 5-aza-2′-deoxycytidine), an analogue of deoxycytidine that can 
incorporate into DNA strands and cause DNA demethylation [193] compared to 
vehicle administration in immunocompetent mice induced endometriosis, treated 
also with E2 had alleviated lesion growth, and increased expressions of PR protein, 
and miRNA corresponding to Esr1, Pgr, Hand2, and Hoxa10, (P4 target), but not 
for Ccl5 and Ptgs2 in the eutopic endometrium and ectopic sites. The results of the 
study enable the authors to review the involvement of estrogens and progesterone 
in eutopic and ectopic endometrium, the epigenetic regulation including DNA 
methylation, the fact that ERα and ERβ (ESR1 and ESR2), PRs (PRA and B), as well 
as PR-targets Hoxa10, Gata2/6, and Hand2 are susceptible to DNA methyltransfer-
ases, leading to an aberrant expression of these molecules in endometriosis.
Early studies showed that the promoter sequences of ERα and ERβ ((ESR1 and 
ESR2), PRs (PR-A and B), as well as PR-targets Hoxa10, Gata2/6, and Hand2 are 
susceptible to DNA methyl transferases, leading to an aberrant expression of these 
molecules in endometrial diseases [194] and loss of PR-mediated signaling during 
disease progression contributes to the increased susceptibility to P4 resistance in 
ill women. Li et al. [114] accepted the proposed role of inflammation to provoke 
widespread changes in the genes and chromatin landscape of lesions, because their 
analyses showed that DNA methylation in PRs and Hoxa10 promoters was enhanced 
in the ectopic lesions in comparison to the normal endometrium, and inhibition 
of genome-wide DNA methylation in female mice restrained lesion expansion and 
partially restored target gene expression.
6. Conclusions
Endometriosis is a chronic disease, with possible onset in embryonic life, latency 
in childehood, reactivation from the menarche, with clinical symptoms and signs 
difficult to be early accurate assessed during reproductive years. Endometriosis 
has a progressive evolution, which drives through tissue intrinsic properties to 
increase lesions size and number, and to functional damages of original eutopic 
endometrium. The cascade of dysregulations in chromatin machinery is difficult 
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to be stopped by hormone therapy and surgery (associated in different strategies), 
when the abnormal signaling of steroid hormones has started: endometrial estrogen 
dominance and progesterone attenuate response up to progesterone resistance, 
because their genes epigenetic disorders. The 7–12 years delay in diagnosis and 
proper therapy drives to accentuation of chronic pelvic pains, dyspareunia, dysche-
zia, infertility/subfertility.
The best therapy is to avoid the dysregulation of steroid hormones signaling, 
induced initially in ectopic and later in eutopic endometrial stroma and glands, to 
maintain or to restore the estrogen/progesterone receptors natural balance, which 
may be possible when an early intervention, from the menarche. One may discuss 
about timing in starting HT in adolescent girls with family history of endometriosis, 
precocious dysmenorrheal, menorrhagia, abundant blood and clots loss, favorising 
menstrual blood reflux.
First line therapy is progesterone/progestins, working in prevention of estrogen 
dominance and progesterone dysregulated signals, and can maintain their positive 
effects, when it is early administrated, as animal models have shown. One must 
recommend this first line therapy, for a long time duration, with a single drug 
(micronized progesterone, or dienogest, a new progestin) or combined with a syn-
thetic/natural estrogen in COCs, in cyclic or in continuous/extended regimens up 
to response failure, with the advice to avoid drug discontinuation. Vaginal route for 
micronized progesterone, IUD with progesterone/levonorgestrel may work better 
for alleviation of estrogen dominance and progesterone resistance.
GnRH agonists/antagonists- second line therapy, are active in correcting the 
steroid imbalance, but less than our expectances, even with the new oral molecules 
(as elagolix), or combination of molecules [GnRH antagonists (relugolix or elago-
lix) plus an estrogen, or plus an estrogen and a progestin], which were proposed to 
avoid or to reduce add back therapy. The most recent studied molecule of elagolix 
may be used no longer than 24 months, because a longer administration may impose 
add back therapy.
Aromatase inhibitors are also second line therapy, recommended in selected 
patients for refractory endometriosis, with chronic pelvic pains. Letrozole com-
bination to norethindrone acetate is better than the progestin alone in correcting 
estrogen dominance, and progesterone resistance.
The new therapeutic perspectives regarding the combination of ER agonists 
with co-activators, and DNA methylation inhibitors are still in studies at high level 
technology laboratories, not for current medical use.
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